Literature DB >> 10624951

Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice.

C J Cummings1, E Reinstein, Y Sun, B Antalffy, Y Jiang, A Ciechanover, H T Orr, A L Beaudet, H Y Zoghbi.   

Abstract

Mutant ataxin-1, the expanded polyglutamine protein causing spinocerebellar ataxia type 1 (SCA1), aggregates in ubiquitin-positive nuclear inclusions (NI) that alter proteasome distribution in affected SCA1 patient neurons. Here, we observed that ataxin-1 is degraded by the ubiquitin-proteasome pathway. While ataxin-1 [2Q] and mutant ataxin-1 [92Q] are polyubiquitinated equally well in vitro, the mutant form is three times more resistant to degradation. Inhibiting proteasomal degradation promotes ataxin-1 aggregation in transfected cells. And in mice, Purkinje cells that express mutant ataxin-1 but not a ubiquitin-protein ligase have significantly fewer NIs. Nonetheless, the Purkinje cell pathology is markedly worse than that of SCA1 mice. Taken together, NIs are not necessary to induce neurodegeneration, but impaired proteasomal degradation of mutant ataxin-1 may contribute to SCA1 pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624951     DOI: 10.1016/s0896-6273(00)81035-1

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  109 in total

1.  Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease.

Authors:  E Martín-Aparicio; A Yamamoto; F Hernández; R Hen; J Avila; J J Lucas
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 2.  Nuclear ataxias.

Authors:  Harry T Orr
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-05       Impact factor: 10.005

3.  Altered neurotransmitter release machinery in mice deficient for the deubiquitinating enzyme Usp14.

Authors:  Bula J Bhattacharyya; Scott M Wilson; Hosung Jung; Richard J Miller
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-09       Impact factor: 4.249

4.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

5.  Inefficient degradation of truncated polyglutamine proteins by the proteasome.

Authors:  Carina I Holmberg; Kristine E Staniszewski; Kwame N Mensah; Andreas Matouschek; Richard I Morimoto
Journal:  EMBO J       Date:  2004-10-07       Impact factor: 11.598

6.  Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.

Authors:  Gustavo Martínez-Noël; Jeffrey T Galligan; Mathew E Sowa; Verena Arndt; Thomas M Overton; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

7.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Authors:  Christophe Lo Bianco; Bernard L Schneider; Matthias Bauer; Ali Sajadi; Alexis Brice; Takeshi Iwatsubo; Patrick Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-02       Impact factor: 11.205

8.  Genetic evidence linking age-dependent attenuation of the 26S proteasome with the aging process.

Authors:  Ayako Tonoki; Erina Kuranaga; Takeyasu Tomioka; Jun Hamazaki; Shigeo Murata; Keiji Tanaka; Masayuki Miura
Journal:  Mol Cell Biol       Date:  2008-12-15       Impact factor: 4.272

Review 9.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

10.  Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

Authors:  Elizabeth J Slow; Rona K Graham; Alexander P Osmand; Rebecca S Devon; Ge Lu; Yu Deng; Jacqui Pearson; Kuljeet Vaid; Nagat Bissada; Ronald Wetzel; Blair R Leavitt; Michael R Hayden
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.